Moving Forward , The Countdown Begins, page-3

Hi Cainy

Yes to Covid Trialing but regrettably Phase II Oncology Trials are not cheap, PAA Management need to be Prudent and Smart and pick "Technically" achievable realistic targets "Low hanging fruit"

The Company has strongly signaled they have serious interest in the K9 Lymphoma Treatment. Sounds like dollars waiting for the results. IMHO

The Covid Human Trial would benefit from the Phase I / 2 Data gained from the MND trial identifying the Goldilocks dose.

MND Orphan Drug Status processing period is limited to only 90 days, also there is no application fee which fits well with our current financial position.

As much as I would love to say " Push the Button on everything" being realistic with the funds at hand plus the timing of incoming revenue from licensing or outright sale of the K9 Treatment, these Catalysts should stimulate the SP into the Oppies which would then return enough working Capital to not only start and finish a Phase II Oncology Trial but place PAA is a strong financial position to carry out multiple trials for other viral infections, the data is deep if you look back over the past 5 years ,




The ONJF Trialed MPL across 30 Human Cancers including Ovarian and Breast Cancer ,,28 Cancers showed
a positive response to being treated with MPL...
10th September 2018 – Perth, Australia: PharmAust Limited (ASXAA), a clinicalstage oncology company,
is pleased to announce independent confirmation of the investigational drug monepantel’s (MPL’s) in vitro
anti-cancer activity by researchers at the Olivia Newton-John Cancer Research Institute (ONJCRI).

Specifically, researchers at the ONJCRI confirmed sensitivity of human brain, breast,
ovarian and prostate cancer cell lines to MPL treatment. The researchers further
demonstrated sensitivity of previously untested human melanoma cancer cell lines, thus
widening the possible reach of MPL’s anti-cancer targets. Two non-cancerous ovarian
cell lines were relatively insensitive to MPL, consistent with MPL’s specificity for cancer
cells.
These data corroborate internal R&D at PharmAust that had previously identified
28 independent cancer cell lines that were sensitive in culture to treatment with MPL,
whereas three non-cancer cell lines were relatively insensitive.

The investigations also demonstrated that the longer cancer cell lines are exposed to MPL,
the greater the anti-cancer activity. For most of the cancer cell lines tested, significant and
progressive increases in the effects of MPL were observed over a one to five-day time
frame. Research into the molecular cascade activated by MPL to exert anti-cancer activity
is now being extended. The work conducted by the ONJRCI is supported in part by a
$50,000 Innovation Connections grant from the Commonwealth Department of Industry,
Innovation and Science.
PharmAust’s Chief Scientific Officer Dr Richard Mollard commented, “Independent
confirmation of MPL’s anticancer activity in specific cancer cell lines is a great milestone
for PharmAust. This work enables PharmAust to progress through its R&D program with
greater certainty and expand its intellectual property portfolio on the mechanisms
underpinning MPL’s mode of action.”


It's all in the hands of Management now, with implications of the Pandemic now subsided , results will be key..

I'm from the school of hard knocks
You get absolutely no merit for Effort only for delivered Results...NZT